Plain-English translation of NCT06005818 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new blood test called Signatera can help doctors make smarter decisions about treating kidney cancer after surgery. The blood test looks for tiny traces of cancer DNA that might be left in your body. If the test is negative (meaning no cancer DNA is found), you may not need additional medication. If it's positive, you would receive pembrolizumab, an immune-boosting medication, to help prevent the cancer from coming back.
After surgery to remove a kidney tumor, doctors usually give all patients the same follow-up treatment, even though some patients may not need it. This trial is testing whether the blood test can identify which patients truly need the medication and which ones can safely avoid it—reducing unnecessary treatment and its side effects.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first have the blood test (Signatera) performed to look for remaining cancer DNA. Depending on your results, you will either enter the observation group (if the test is negative and you simply have follow-up visits and scans) or the treatment group (if the test is positive and you receive the medication pembrolizumab every 6 weeks for one year). The study lasts about one year, with regular clinic visits to check your health, monitor for side effects, and perform imaging scans to make sure the cancer hasn't returned.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States